SG11201906190YA - Universal influenza vaccine compositions - Google Patents

Universal influenza vaccine compositions

Info

Publication number
SG11201906190YA
SG11201906190YA SG11201906190YA SG11201906190YA SG11201906190YA SG 11201906190Y A SG11201906190Y A SG 11201906190YA SG 11201906190Y A SG11201906190Y A SG 11201906190YA SG 11201906190Y A SG11201906190Y A SG 11201906190YA SG 11201906190Y A SG11201906190Y A SG 11201906190YA
Authority
SG
Singapore
Prior art keywords
international
virus
memory
vaccine
cell activation
Prior art date
Application number
SG11201906190YA
Inventor
Ramila Philip
Original Assignee
Emergex Vaccines Holding Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergex Vaccines Holding Ltd filed Critical Emergex Vaccines Holding Ltd
Publication of SG11201906190YA publication Critical patent/SG11201906190YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

FigAg Processing/presentation CD4+CD8+T cell Activation CD4+CD8+memory Ideal Vaccine Responses T cell epitope vaccine Viral peptides Antibody secrection Memory B cells develop T cell Killing of virus-infected cells Virus (or viral proteins) B cell activation 4 4 4 CD4+CD8+T cell Activation CD4+CD8+memory T cells develop Antibody secretion Memory B cells develop Ag Uptake/presentation Subunit vaccine B cell activation cc N Virus infection (Challenge) Virus neutralization by antibodies (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 12 July 2018 (12.07.2018) WIP0 1 PCT Iiiimmomiolollmonolomomolomimionomovois (10) International Publication Number WO 2018/127689 Al (51) International Patent Classification: A61K 39/12 (2006.01) (21) International Application Number: PCT/GB2018/050004 (22) International Filing Date: 03 January 2018 (03.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/441,659 03 January 2017 (03.01.2017) US (71) Applicant: EMERGEX VACCINES HOLDINGS LTD [GB/GB]; 4/5 Dunmore Court, Wootton Road, Abingdon Oxfordshire OX13 6BH (GB). (72) Inventor: PHILIP, Ramila; 115 Golfview Drive, Ivyland, Pennsylvania 18974 (US). (74) Agent: J A KEMP; 14 South Square, Gray's Inn, London Greater London WC1R 5JJ (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) = (54) Title: UNIVERSAL INFLUENZA VACCINE COMPOSITIONS el (57) : The invention provides a vaccine composition comprising an influenza virus peptide comprising a CD8+ T cell epitope 0 and an influenza virus peptide comprising a B cell epitope, wherein each peptide is attached to a nanoparticle.
SG11201906190YA 2017-01-03 2018-01-03 Universal influenza vaccine compositions SG11201906190YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762441659P 2017-01-03 2017-01-03
PCT/GB2018/050004 WO2018127689A1 (en) 2017-01-03 2018-01-03 Universal influenza vaccine compositions

Publications (1)

Publication Number Publication Date
SG11201906190YA true SG11201906190YA (en) 2019-08-27

Family

ID=60957339

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906190YA SG11201906190YA (en) 2017-01-03 2018-01-03 Universal influenza vaccine compositions

Country Status (13)

Country Link
US (2) US11273216B2 (en)
EP (1) EP3565590A1 (en)
JP (1) JP2020504179A (en)
CN (1) CN110290805A (en)
AU (1) AU2018206291A1 (en)
BR (1) BR112019013724A2 (en)
CA (1) CA3049190A1 (en)
EA (1) EA201991377A1 (en)
MX (1) MX2019007973A (en)
PH (1) PH12019501569A1 (en)
SG (1) SG11201906190YA (en)
WO (1) WO2018127689A1 (en)
ZA (1) ZA201904505B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112654364A (en) * 2018-05-18 2021-04-13 埃默杰克斯疫苗控股有限公司 Reverse peptide vaccine
WO2020257315A1 (en) * 2019-06-18 2020-12-24 Citranvi Biosciences, Llc Multiple antigen protein displayed adjuvant systems
CN111440246B (en) * 2020-04-16 2022-03-18 成都仕康美生物科技有限公司 Chimeric antigen receptor targeting HLA-B, encoding gene, CAR-Tregs cell and preparation method and application thereof
GB202008250D0 (en) * 2020-06-02 2020-07-15 Emergex Vaccines Holding Ltd Diagnosis, prevention and treatment of coronavirus infection
CN117402213B (en) * 2023-10-24 2024-04-05 暨南大学附属第六医院(东莞市东部中心医院) Influenza A virus CD8+ T cell epitope peptide and application thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002223398A1 (en) * 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
GB0025414D0 (en) 2000-10-16 2000-11-29 Consejo Superior Investigacion Nanoparticles
US9079765B2 (en) 2004-10-01 2015-07-14 Midatech Ltd. Nanoparticles comprising antigens and adjuvants, and immunogenic structures
KR20080028941A (en) * 2005-07-19 2008-04-02 다우 글로벌 테크놀로지스 인크. Recombinant flu vaccines
EP1919507A2 (en) 2005-08-04 2008-05-14 Thomas William Rademacher Nanoparticles comprising antibacterial ligands
ES2369608T3 (en) 2006-04-13 2011-12-02 Midatech Ltd. NANOPARTICLES CONTAINING THREE DIFFERENT LIGANDS TO PROVIDE IMMUNE RESPONSES AGAINST INFECTIVE AGENTS.
CA2713879C (en) * 2008-02-01 2020-01-07 Alpha-O Peptides Ag Self-assembling peptide nanoparticles useful as vaccines
CA2793772A1 (en) * 2010-03-26 2011-09-29 Emergent Product Development Gaithersburg Inc. Ectodomains of influenza matrix 2 protein, expression system, and uses thereof
JP6077544B2 (en) 2011-09-07 2017-02-08 ミダテック リミテッド Nanoparticle-peptide composition
WO2013059403A1 (en) * 2011-10-19 2013-04-25 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of influenza virus infection
MX2014014683A (en) * 2012-06-06 2015-02-24 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants.
CN103705917A (en) * 2012-09-28 2014-04-09 中国农业科学院上海兽医研究所 M2e synthetic peptide swine influenza virus general vaccine and application

Also Published As

Publication number Publication date
JP2020504179A (en) 2020-02-06
EP3565590A1 (en) 2019-11-13
ZA201904505B (en) 2023-03-29
CN110290805A (en) 2019-09-27
US11273216B2 (en) 2022-03-15
PH12019501569A1 (en) 2021-02-08
MX2019007973A (en) 2019-11-18
AU2018206291A1 (en) 2019-07-25
WO2018127689A1 (en) 2018-07-12
CA3049190A1 (en) 2018-07-12
EA201991377A1 (en) 2020-01-21
US20190321460A1 (en) 2019-10-24
BR112019013724A2 (en) 2020-04-14
US20220233679A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
SG11201906190YA (en) Universal influenza vaccine compositions
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201804411TA (en) Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201907402SA (en) Population-based immunogenic peptide identification platform
SG11201908813QA (en) Anti-sirp alpha antibodies
SG11201809336QA (en) Anti-pd-l1 antibodies
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201906198PA (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
SG11201900482SA (en) Compounds and compositions as inhibitors of endosomal toll-like receptors
SG11201909153UA (en) Peptides and combination thereof for use in the immunotherapy against cancers
SG11201807590SA (en) Transfected t-cells and t-cell receptors for use in immunotherapy against cancers
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201807912SA (en) Vaccine against rsv
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201901790YA (en) Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
SG11201811442UA (en) Formulation of a peptide vaccine
SG11201806419RA (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201909265QA (en) Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
SG11201900021PA (en) Methods and compositions for the treatment of cancer